Trial Profile
Pharmacokinetics, pharmacodynamics and tolerability of ORG 43553 in female volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Oct 2013
Price :
$35
*
At a glance
- Drugs ORG 43553 (Primary) ; Ganirelix; Recombinant follicle-stimulating hormone
- Indications Infertility
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
- Sponsors Merck Sharp & Dohme
- 31 Oct 2013 New trial record